Q1 25 EPS
$-0.24
BEAT +10.21%
Est. $-0.27
Q1 25 Revenue
$255.7M
BEAT +3.07%
Est. $248.1M
vs S&P Since Q1 25
-21.7%
TRAILING MARKET
TEM +8.2% vs S&P +29.9%
Market Reaction
Did TEM Beat Earnings? Q1 2025 Results
Tempus AI delivered a notably strong first quarter for 2025, beating Wall Street expectations on both the top and bottom lines as its expanding genomics business and high-margin data services drove momentum across the organization. The company posted… Read more Tempus AI delivered a notably strong first quarter for 2025, beating Wall Street expectations on both the top and bottom lines as its expanding genomics business and high-margin data services drove momentum across the organization. The company posted a Non-GAAP loss of $0.24 per share, ahead of the $0.27 consensus estimate by 10.21%, while revenue climbed 75.4% year-over-year to $255.74 million, topping forecasts by 3.07%. The primary engine behind that growth was the February completion of the Ambry Genetics acquisition, which propelled Genomics segment revenue up 88.9% and contributed $63.50 million in hereditary testing revenue alone. Gross margin expanded meaningfully to 60.7% from 53.3% a year ago, reflecting improving operating leverage across both business segments. Investors watching Tempus closely also got a forward-looking boost, as the company raised full-year 2025 revenue guidance to approximately $1.25 billion, representing roughly 80% annual growth, and now projects positive Adjusted EBITDA of $5 million for the year, a roughly $110 million improvement over 2024.
Key Takeaways
- • Genomics revenue grew 88.9% YoY driven by Ambry Genetics acquisition and organic oncology testing growth
- • Oncology testing volume growth of approximately 20%
- • Hereditary testing unit growth of approximately 23%
- • Insights (data licensing) revenue grew 58.0% YoY
- • Gross margin improvement in both Genomics (56.3% vs 48.5%) and Data and services (74.6% vs 64.7%)
- • Significant operating leverage with Adjusted EBITDA improving $27.8 million YoY
TEM YoY Financials
Q1 2025 vs Q1 2024, source: SEC Filings
TEM Revenue by Segment
With YoY comparisons, source: SEC Filings
“The business is performing well with revenues growing, margins improving, and our costs remaining in check, allowing us to demonstrate significant year-over-year operating leverage. Our strategic investments in AI have us uniquely positioned to advance what is possible in diagnostics and drug development, as evidenced by our announcement to build the largest foundation model in oncology with AstraZeneca and Pathos. We believe this is just the beginning as more and more healthcare providers and life science companies embrace AI.”
— Eric Lefkofsky, Q1 2025 Earnings Press Release
TEM Earnings Trends
TEM vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
TEM EPS Trend
Earnings per share: estimate vs actual
TEM Revenue Trend
Quarterly revenue: estimate vs actual
TEM Quarterly Results
5 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q1 26 BEAT | $-0.20 | $-0.13 | +35.36% | $348.1M | +0.78% |
| Q4 25 BEAT FY | $-0.05 | $-0.04 | +22.03% | $367.2M | +1.05% |
| FY Full Year | — | $-0.61 | — | $1.27B | — |
| Q3 25 BEAT | $-0.18 | $-0.11 | +37.25% | $334.2M | +1.68% |
| Q2 25 BEAT | $-0.25 | $-0.25 | +1.15% | $314.6M | +5.67% |
| Q1 25 BEAT | $-0.27 | $-0.24 | +10.21% | $255.7M | +3.07% |